Detalhe da pesquisa
1.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Cell
; 167(6): 1540-1554.e12, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27912061
2.
Unique pattern of neutrophil migration and function during tumor progression.
Nat Immunol
; 19(11): 1236-1247, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323345
3.
Ferroptosis of tumour neutrophils causes immune suppression in cancer.
Nature
; 612(7939): 338-346, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385526
4.
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.
Immunity
; 49(1): 178-193.e7, 2018 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29958801
5.
EMT and dissemination precede pancreatic tumor formation.
Cell
; 148(1-2): 349-61, 2012 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22265420
6.
Fatty acid transport protein 2 reprograms neutrophils in cancer.
Nature
; 569(7754): 73-78, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30996346
7.
An open protocol for modeling T Cell Clonotype repertoires using TCRß CDR3 sequences.
BMC Genomics
; 24(1): 349, 2023 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37365517
8.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Nature
; 545(7652): 60-65, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28397821
9.
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Proc Natl Acad Sci U S A
; 117(14): 8022-8031, 2020 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213589
10.
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Lancet Oncol
; 23(8): 1009-1020, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810751
11.
CD40 Agonist Antibodies in Cancer Immunotherapy.
Annu Rev Med
; 71: 47-58, 2020 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31412220
12.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol
; 22(1): 118-131, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387490
13.
A unique window of opportunity for practical reform of cancer clinical trials.
Cancer
; 127(16): 2855-2860, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33849079
14.
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.
Oncologist
; 26(4): 269-273, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33465258
15.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Nature
; 520(7547): 373-7, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25754329
16.
Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.
Proc Natl Acad Sci U S A
; 114(7): 1655-1659, 2017 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28137880
17.
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Biol Blood Marrow Transplant
; 25(3): 515-521, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30315941
18.
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
Blood
; 129(7): 906-916, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057639
19.
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
Biol Blood Marrow Transplant
; 24(3): 594-599, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061535
20.
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Br J Cancer
; 119(10): 1200-1207, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318516